Key Points Johnson & Johnson will acquire Intra-Cellular Therapies for $14.6 billion. The deal values Intra-Cellular shares at $132 each, a 39% premium. Intra-Cellular’s Caplyta drug generated $175 million in Q3 2024 sales. Analysts expect Caplyta’s sales to top $2.5 billion by 2028. Intra-Cellular’s pipeline includes treatments for Alzheimer ’s-related agitation. The acquisition is expected to close later this year, pending regulatory approval. Johnson & Johnson (J&J) has announced plans to strengthen its presence in treating central nervous system disorders...